1. Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors. (December 2016) Authors: Hyman, D.; Chatterjee, M.; Langenberg, M.H.G.; Lin, C.C.; Suárez, C.; Tai, D.; Cassier, P.; Yamamoto, N.; De Weger, V.A.; Jeay, S.; Meille, C.; Halilovic, E.; Mariconti, L.; Guerreiro, N.; Kumar, A.; Wuerthner, J.U.; Bauer, S. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. (December 2016) Authors: Carita, G.; Frisch-Dit-Leitz, E.; Dahmani, A.; Raymondie, C.; Cassoux, N.; Piperno-Neumann, S.; Némati, F.; Laurent, C.; De Koning, L.; Halilovic, E.; Jeay, S.; Wylie, A.; Emery, C. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗